May 1, 2024 Biosimilar 0 Comments FDA’s Biosimilars Action Plan – Healthcare Economist In July 2018, FDA released the Biosimilars Action Plan (BAP), which outlined FDA’s approach for expanding access to biosimilars ... Read More
April 9, 2024 EMA 0 Comments EMA and delays in drug launch – Healthcare Economist For patients with serious illnesses, timeline access to efficacious medications is paramount. The European Medicines Agency (EMA) was created in part to help expedite ... Read More